Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML
Part of the
Haematology and Blood Transfusion / Hämatologie und Bluttransfusion
book series (HAEMATOLOGY, volume 34)
A body of in vitro evidence suggests that use of granulocyte-macrophage colony-stimulating factor (GM-CSF) might increase the in vivo sensitivity of leukemic myeloblasts to daunorubicin-cytosine arabinoside (ara-C) chemotherapy [1–4]. If so, administration of GM-CSF prior to and during administration of daunorubicin/ara-C might overcome the resistance to therapy that is characteristic of acute myeloid leukemia (AML). This resistance is most obvious in patients with abnormalities of chromosomes 5, 7, (−5, −7, 5q-, 7q-) who frequently fail even to enter initial complete remission (CR), but it is also a major problem in patients with other aneuploidies (except INV(16), t (15; 17), or t (8; 21)), or with a normal karyotype or insufficient metaphases for analysis .While the majority of these patients enter CR, their remissions rarely last more than 2 years.
KeywordsAcute Myeloid Leukemia Chronic Myeloid Leukemia Acute Promyelocytic Leukemia Acute Myelogenous Leukemia Myeloid Blast Crisis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Cannistra SA, Groshek P, Griffin JD (1989) Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis of chronic myeloid leukemia. Leukemia 3: 328–334PubMedGoogle Scholar
Hiddemann W, Kiehl M, Schleyer E, Woermann B, Zuehlsdorf M, Buechner T (1989) Stimulating effect of GM-CSF and IL-3 on the metabolism and cytotoxic activity of cytosine arabinoside in leukemia blasts from patients with acute myeloid leukemia. Blood 74 (Suppl 1): 230aGoogle Scholar
Santini V, Noater K, Delwel R, Loewenberg B (1990) Susceptibility of acute myeloid leukemia cells from clinically resistant and sensi tive patient to daunomycin: assessment in vitro after stimulation with colony stimulating factors. Leuk Res 14: 377–380PubMedCrossRefGoogle Scholar
Tafuri A, Andreeff M (1990) Kinetic rationale for cytokine-induced recruitment of myelo blastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4: 826–835PubMedGoogle Scholar
Keating M, Cork A, Broach Y, Smith T, Walters R, McCredie K, Trujillo J, Freireich E (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res: 119–133Google Scholar
Cassileth PA, Harrington DP, Hines JD, Oken MM, Maza JJ, McGlave P, O’Connell MJ (1988) Maintenance chemotherapy prolongs remission duration in adult acute none lymphocytic leukemia. J Clin Oncol 6: 583–587PubMedGoogle Scholar
Keating M, Smith T, Kantarjian H, Cork A, Walters R, Trujillo J, McCredie K, Gehan E, Freireich E (1988) Cytogenetic pattern in acute myelogenous leukemia: a major repro ducible determinant of outcome. Leukemia 2: 403–412PubMedGoogle Scholar
Estey E, Smith T, Keating M, McCredie K, Gehan E, Freireich E (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myelogenous leukemia. Leukemia 3: 257–263PubMedGoogle Scholar
© Springer-Verlag Berlin Heidelberg 1992